One clinical trial did also link another JAK2 inhibitor with decreased inflammatory cytokines, reduced splenomegaly and the exertion of immunomodulatory effects (ClinicalTrials.gov Identifier: NCT01437787) [140]. The gene discussed is JAK2; the disease is Splenomegaly.